- Home
- RIGL vs HKD Comparison
RIGL vs HKD Comparison
Compare RIGL & HKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- HKD
- Stock Information
- Founded
- RIGL 1996
- HKD 2003
- Country
- RIGL United States
- HKD France
- Employees
- RIGL N/A
- HKD 199
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- HKD Finance: Consumer Services
- Sector
- RIGL Health Care
- HKD Finance
- Exchange
- RIGL Nasdaq
- HKD Nasdaq
- Market Cap
- RIGL 486.4M
- HKD 505.3M
- IPO Year
- RIGL 2000
- HKD 2022
- Fundamental
- Price
- RIGL $20.09
- HKD $2.63
- Analyst Decision
- RIGL Buy
- HKD
- Analyst Count
- RIGL 5
- HKD 0
- Target Price
- RIGL $34.80
- HKD N/A
- AVG Volume (30 Days)
- RIGL 223.6K
- HKD 536.8K
- Earning Date
- RIGL 03-04-2025
- HKD 01-01-0001
- Dividend Yield
- RIGL N/A
- HKD N/A
- EPS Growth
- RIGL N/A
- HKD N/A
- EPS
- RIGL 0.22
- HKD 0.33
- Revenue
- RIGL $157,374,000.00
- HKD $27,776,448.00
- Revenue This Year
- RIGL $51.34
- HKD N/A
- Revenue Next Year
- RIGL $15.75
- HKD N/A
- P/E Ratio
- RIGL $91.32
- HKD $8.13
- Revenue Growth
- RIGL 21.65
- HKD N/A
- 52 Week Low
- RIGL $7.48
- HKD $2.55
- 52 Week High
- RIGL $29.82
- HKD $5.80
- Technical
- Relative Strength Index (RSI)
- RIGL 45.75
- HKD 45.03
- Support Level
- RIGL $20.00
- HKD $2.60
- Resistance Level
- RIGL $21.93
- HKD $2.84
- Average True Range (ATR)
- RIGL 1.30
- HKD 0.17
- MACD
- RIGL -0.27
- HKD -0.01
- Stochastic Oscillator
- RIGL 2.01
- HKD 8.00
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About HKD AMTD Digital Inc. (every five of which represent two)
AMTD Digital Inc along with its subsidiaries, is mainly involved in the provision of digital solutions services. The company integrates various digital businesses using its AMTD SpiderNet ecosystem. Its reportable segments are; digital solutions services financial services; digital solutions services non-financial services, hotel operations, hospitality and VIP services, digital media, content and marketing services, and others. The company generates maximum revenue by providing financial digital solutions through its AMTD Risk Solutions, a digital insurance brokerage platform, and PolicyPal which is a digital insurance technology platform. Geographically, the company generates maximum revenue from Hong Kong and the rest from Canada and Singapore.